



## **JAGSONPAL PHARMACEUTICALS LIMITED**

Regd. Office : T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA)

Fax : 0091-11-26498341, 26494708, Phone : 0091-11-26494519-24

CIN No. L74899DL1978PLC009181

Date: November 10<sup>th</sup>, 2020

To, The Department of Corporate Services- Listing <b>BSE Limited</b> Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400 001	To, The Manager- Listing <b>National Stock Exchange of India Ltd.</b> Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051
<b>Scrip Code: 507789</b>	<b>Symbol: JAGSNPHARM</b>

**SUB: SUBMISSION OF UN-AUDITED FINANCIAL RESULTS ALONG WITH LIMITED REVIEW REPORT FOR THE QUARTER AND HALF YEAR ENDED 30<sup>TH</sup> SEPTEMBER, 2020.**

Dear Sir,

In terms of the provisions of Regulation 33 (3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Un-Audited Financial Results for the Quarter and Half Year ended 30<sup>th</sup> September, 2020 duly approved by the Board at its meeting held on 10<sup>th</sup> November, 2020.

The Limited Review Report on the Un-Audited Financial Results for the Quarter and Half Year ended 30<sup>th</sup> September, 2020 in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure requirements) Regulations 2015 is also enclosed herewith.

Kindly take the above on record & oblige.

Thanking You,

**For JAGSONPAL PHARMACEUTICALS LIMITED**


**Nandita Singh**

**Company Secretary & Compliance Officer**



## LIMITED REVIEW REPORT

The Board of Directors  
Jagsonpal Pharmaceuticals Limited  
T-210-J, Shahpur Jat  
New Delhi-110049

1. We have reviewed the accompanying statement of Unaudited Financial Results of Jagsonpal Pharmaceuticals Limited (the "Company") for the Quarter and Half Year ended 30<sup>th</sup> September, 2020. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For H. L. Bansal & Co.  
Chartered Accountants  
Firm Registration Number: 008563N



H. L. Bansal  
Partner

Membership Number: 086990

UDIN-20086990AAAAEY1476

Date: 10<sup>th</sup> November, 2020  
Place: New Delhi



## JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office : T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA)

Fax : 0091-11-26498341, 26494708, Phone : 0091-11-26494519-24

CIN No. L74899DL1978PLC009181

### Statement of Standalone Unaudited Financial Results for the Quarter and Half Year Ended 30.09.2020

Rs. Lakhs

	Particulars	Standalone					12 Months
		Quarter Ended			Half Year Ended		Year Ended
		30.09.2020	30.06.2020	30.09.2019	30.09.2020	30.09.20	31.03.2020
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
<b>1</b>	<b>Income from operations</b>						
a	Gross Sales/Revenue from Operations	5635.27	3165.21	4180.59	8800.48	8703.99	15856.78
b	Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
	<b>Total Income from operations</b>	<b>5635.27</b>	<b>3165.21</b>	<b>4180.59</b>	<b>8800.48</b>	<b>8703.99</b>	<b>15856.78</b>
<b>2</b>	<b>Other Income</b>	41.35	78.45	44.38	119.80	111.50	252.62
<b>3</b>	<b>Total Income [ 1+2]</b>	<b>5676.62</b>	<b>3243.66</b>	<b>4224.97</b>	<b>8920.28</b>	<b>8815.49</b>	<b>16109.40</b>
<b>4</b>	<b>Expenses</b>						
a	Cost of materials consumed	1090.61	440.2	756.22	1530.81	1929.35	3678.48
b	Purchases of stock-in-trade	933.35	234.74	461.38	1168.09	936.21	1815.19
c	Changes in inventories of finished goods, work in progress and Stock in trade	765.48	579.69	371.10	1345.17	572.21	124.99
d	Excise Duty	0.00		0.00	0.00	0.00	0.00
e	Employee benefits expenses	1565.80	1181.98	1246.90	2747.78	2561.41	5037.42
f	Finance Cost	11.69	13.09	14.81	24.78	26.58	51.41
g	Depreciation and amortisation	27.46	27.45	26.72	54.91	55.33	112.98
h	Other expenses	796.61	463.98	1094.21	1260.59	2230.31	4347.45
	<b>Total expenses</b>	<b>5190.99</b>	<b>2941.13</b>	<b>3971.34</b>	<b>8132.12</b>	<b>8311.40</b>	<b>15167.92</b>
<b>5</b>	<b>Profit before exceptional items and taxes (3-4)</b>	<b>485.63</b>	<b>302.53</b>	<b>253.63</b>	<b>788.16</b>	<b>504.09</b>	<b>941.48</b>
6	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
<b>7</b>	<b>Profit before tax [5-6]</b>	<b>485.63</b>	<b>302.53</b>	<b>253.63</b>	<b>788.16</b>	<b>504.09</b>	<b>941.48</b>
8	Tax expense	84.75	50.50	50.72	135.25	100.81	154.40
<b>9</b>	<b>Net Profit for the period [7-8]</b>	<b>400.88</b>	<b>252.03</b>	<b>202.91</b>	<b>652.91</b>	<b>403.28</b>	<b>787.08</b>
10	Other Comprehensive Income						
A	(i) Items that will not be classified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will not be reclassified to profit and loss	0.00	0.00	0.00	0.00	0.00	0.00
<b>11</b>	<b>Total Other Comprehensive Income [A(i) + A(ii)]</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>12</b>	<b>Total Comprehensive Income</b>	<b>400.88</b>	<b>252.03</b>	<b>202.91</b>	<b>652.91</b>	<b>403.28</b>	<b>787.08</b>
13	Paid up Equity Share Capital (Face value Rs. 5/- per share)	1309.90	1309.90	1309.90	1309.90	1309.90	1309.90
<b>14</b>	<b>Earnings Per Share (before and after extraordinary items) (of Rs 5/- each)</b>						
a.	Basic (Rs.)	1.53	0.96	0.77	2.49	1.54	3.00
b.	Diluted (Rs.)	1.53	0.96	0.77	2.49	1.54	3.00






**Statement of Assets and Liabilities for the half year ended 30.09.2020**

Rs. In Lakhs

	Particulars	As on 30.09.2020 (Unaudited)	As on 31.03.2020 (Audited)
<b>ASSETS</b>			
1	<b>Non-current assets</b>		
	(a) Property, Plant and Equipment	2142.37	2206.02
	(b) Capital Work-in-Progress	190.34	190.34
	(c) Intangible assets	237.53	237.53
	(e) Financial assets		
	(i) Investments	1145.86	1138.68
	(ii) Loans	51.72	
	Non-current tax assets (net)	1464.00	
	Deferred tax assets (net)		
	Other non-current assets	12.96	1431.91
	<b>Total non-current assets</b>	<b>5244.78</b>	<b>5204.48</b>
2	<b>Current assets</b>		
	(a) Inventories	1544.80	2932.50
	Financial assets		
	(i) Investments	100.00	
	(ii) Loans	23.96	
	(iii) Trade receivables	3258.98	2145.34
	(iv) Cash and cash equivalents	5590.45	3981.31
	(v) Bank balances other than (iv) above	79.60	
	(vi) Other	16.65	
	Other current assets	465.12	605.75
	<b>Total current assets</b>	<b>11079.56</b>	<b>9664.90</b>
	<b>TOTAL ASSETS</b>	<b>16324.34</b>	<b>14869.38</b>
<b>EQUITY AND LIABILITIES</b>			
<b>EQUITY</b>			
	(a) Equity Share Capital	1309.90	1309.90
	(b) Other Equity	10446.39	9793.49
	<b>Total Equity</b>	<b>11756.29</b>	<b>11103.39</b>
<b>LIABILITIES</b>			
1	<b>Non-current liabilities</b>		
	(a) Deferred tax liabilities (Net)	309.16	309.16
	(b) Non current borrowings		
	<b>Non-current liabilities</b>	<b>309.16</b>	<b>309.16</b>
2	<b>Current liabilities</b>		
	Financial liabilities		
	(i) Borrowings	659.57	640.37
	(ii) Trade payables		
	-total outstanding dues of micro enterprises and small enterprises	165.05	275.98
	-total outstanding dues of creditor other than micro enterprises and small enterprises	1638.32	894.95
	(iii) Lease liabilities		
	(iv) Other financial liabilities	660.58	
	Provisions		
	Government grants		
	Current tax liabilities	965.23	829.97
	Other current liabilities	170.14	815.56
	<b>Total current liabilities</b>	<b>4258.89</b>	<b>3456.83</b>
	<b>Total Liabilities</b>	<b>4568.05</b>	<b>3765.99</b>
	<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>16324.34</b>	<b>14869.38</b>



*Ram*

Notes	
1	The above Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on 10-11-20
2	In line with the provisions of Ind AS 18 , the Company operates in one reportable business segment i.e. 'Pharmaceuticals'.
3	Figures for the previous periods have been regrouped , wherever necessary, to correspond with the figures of the current period.
4	The above results are available on website of the company www.jagsonpal.com and on the Website of BSE (www.bseindia.com) and NSE (www.nseindia.com).
5	The Company has adopted Ind AS from April 1, 2017 and accordingly, these financial results have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 Interim Financial Reporting prescribed under section 133 of the Companies Act 2013, read with relevant rules issued thereunder.
6	The revenue for the quarter ended 30-09-2020, is reported net of GST.
7	Provision for taxation includes provision for current tax.
By Order of the Board For Jagsonpal Pharmaceuticals Limited	
	
 	
Place : New Delhi	Rajpal Singh Kochhar
Date : 10-11-2020	Managing Director DIN No 00059492

## Statement of Unaudited Cash flows for the Half Year Ended 30th September 2020

Rs. In Lakhs

Particulars	Standalone	
	Unaudited	Unaudited
	Six Months ended Sep 30,2020	Six Months ended Sep 30,2019
<b>Cash flow from operating activities</b>		
<b>Net profit before tax</b>	788.16	504.09
Depreciation and amortisation expense	54.91	55.33
Provision for doubtful debts and advances		
Loss/(Profit) on sale of property, plant and equipment		
Interest Income	(83.55)	(111.50)
Interest expense	19.23	26.58
<b>Operating profit before working capital changes</b>	<b>778.75</b>	<b>474.50</b>
<b>Movement in Working Capital</b>		
(Increase/Decrease in Trade Receivables	(1,106.31)	-797.93
(Increase)/Decrease in Inventories	1,387.70	720.89
(Increase)/Decrease in other Financial Assets	15.98	-2.37
(Increase)/Decrease in other Assets	(15.40)	-23.10
(Increase)/Decrease in Trade Payables	467.28	459.44
Increase in provisions		
Increase in other financial liabilities	328.04	
Increase in other liabilities	(89.51)	
<b>Cash generated from Operations</b>	<b>1,766.53</b>	<b>831.43</b>
Taxes (Paid)/ Refund (net)	(65.00)	-100.81
<b>Net Cash generated from /(used) in Operating Activities</b>	<b>1,701.53</b>	<b>730.62</b>
<b>Cash flow from investing activities</b>		
Purchase of Property, Plant and Equipment and Intangible	(18.08)	(128.35)
Sale proceeds of Property, Plant and Equipment and Intangible	14.50	
Purchase of Investments	(7.18)	(134.25)
Interest Received	71.16	111.50
<b>Net cash flow from / (used in) investing activities (B)</b>	<b>60.40</b>	<b>(151.05)</b>
<b>Cash flow from financing activities</b>		
Repayment of Long-term borrowings		
Proceeds of long-term borrowings	19.20	46.44
Proceeds of short-term borrowings		
Repayment of short-term borrowings		23.90
Interest Paid	(19.23)	(26.50)
Dividend paid	(131.00)	
Dividends Distribution Tax paid		
<b>Net cash generated from / (used in) financing activities C</b>	<b>(131.03)</b>	<b>43.85</b>
<b>Net increase / (decrease) in Cash and cash equivalents (A+B+C)</b>	<b>1,630.90</b>	<b>623.42</b>
Effect of exchange differences on cash and cash equivalents held in foreign Currency		
Cash and cash equivalents at the beginning of the year	3,959.54	3,853.46
Cash and cash equivalents at the end of the year	<b>5,590.44</b>	<b>4,476.88</b>



For Jagsonal Pharmaceuticals Limited

Mg. Director